Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children, adolescents, and adults. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Metrics to compare | CING | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCINGPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.3x | −0.9x | −0.7x | |
PEG Ratio | −0.02 | −0.01 | 0.00 | |
Price/Book | 4.3x | 2.2x | 2.6x | |
Price / LTM Sales | - | 1.7x | 3.4x | |
Upside (Analyst Target) | 393.8% | 200.5% | 35.5% | |
Fair Value Upside | Unlock | 0.0% | 3.3% | Unlock |